A large German health insurer has raised concerns over what its data shows to be an excessive underreporting by government authorities of adverse events after experimental COVID-19 gene-based vaccine injections.
Andreas Schöfbeck, a board member of BKK ProVita, addressed the company’s findings in a formal letter to the government’s Paul Ehrlich Institute (PEI), which had reported earlier this year that there were 244,576 suspected cases of side effects from the gene-based injections in the calendar year 2021.
Speaking to this figure, Schöfbeck wrote:
Explaining that their sample includes 10,937,716 insured clients, with available data covering only the first 7½ months of 2021, their company had already logged 216,695 cases of adverse reactions for COVID-19 gene-based injections.
Extending this rate for the full year, and then applying it to the full population of Germany (around 83 million), one can estimate that likely 2.5 million to 3 million individuals in the nation were treated by medical professionals for such adverse events.
This is a “significant alarm signal,” he said in his letter, as it “means around 4-5% of the vaccinated were under medical treatment for side effects,” a rate about 10 times higher than the government’s reported numbers.